What is the effective dosage of Saccharomyces cerevisiae CBS 5926 for acne?

Clinical studies used specific colony-forming unit doses over 5 months to achieve 74.3% improvement rates. Exact dosing protocols should follow manufacturer guidelines and healthcare provider recommendations.

How long does Saccharomyces cerevisiae CBS 5926 take to work for diarrhea?

Controlled studies show benefits for acute diarrhea typically within 24-72 hours of initiation. Traveler's diarrhea and tube-feeding diarrhea may require several days of consistent supplementation for optimal results.

Can children take Saccharomyces cerevisiae CBS 5926 safely?

Research demonstrates safety in pediatric cystic fibrosis patients, indicating good tolerability in children. However, dosing should be adjusted for pediatric populations and supervised by healthcare providers.

Does Saccharomyces cerevisiae CBS 5926 survive stomach acid?

As a hardy yeast strain, Saccharomyces cerevisiae CBS 5926 demonstrates superior acid resistance compared to bacterial probiotics. This allows viable organisms to reach the intestinal tract where they exert therapeutic effects.

What makes CBS 5926 different from other Saccharomyces cerevisiae strains?

CBS 5926 is a specific strain with documented clinical efficacy for acne and diarrheal conditions in controlled trials. Strain-specific effects mean results from CBS 5926 studies cannot be extrapolated to other Saccharomyces cerevisiae variants.

Is Saccharomyces cerevisiae CBS 5926 safe to take with antibiotics?

Yes, CBS 5926 is safe to take concurrently with antibiotics. Clinical studies in pediatric cystic fibrosis patients receiving antibiotic therapy showed no adverse events, fungemia, or safety concerns when CBS 5926 was administered alongside antimicrobial treatment. This strain is actually beneficial during antibiotic use, as it helps maintain healthy gut flora when antibiotics disrupt the microbiome.

What clinical research supports Saccharomyces cerevisiae CBS 5926 for skin health?

A 5-month randomized controlled trial demonstrated strong evidence for acne reduction, with 74.3% of participants achieving good or very good outcomes compared to only 21.7% in the placebo group. This represents one of the most robust clinical datasets for a probiotic strain in dermatological applications, suggesting CBS 5926 has meaningful anti-inflammatory effects on skin conditions.

Who benefits most from Saccharomyces cerevisiae CBS 5926 supplementation?

CBS 5926 is particularly beneficial for individuals experiencing acute or traveler's diarrhea, those on prolonged antibiotic courses, and people with acne-prone skin seeking natural alternatives. It is also well-suited for pediatric populations, including children with cystic fibrosis, as clinical evidence confirms its safety and efficacy in young patients without fungal complications.

Saccharomyces cerevisiae CBS 5926

Saccharomyces cerevisiae CBS 5926 is a specific probiotic yeast strain that produces beneficial metabolites and strengthens intestinal barrier function. Clinical studies demonstrate significant efficacy for treating acne and various forms of diarrhea through gut-skin axis modulation.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Moderate

Saccharomyces cerevisiae CBS 5926 — Hermetica Encyclopedia

Origin & History

Saccharomyces cerevisiae CBS 5926 is a specific strain of probiotic yeast, also known as S. boulardii Hansen CBS 5926, commercially available as Perenterol. It is produced through fermentation and lyophilization into powder or capsule forms containing viable yeast cells, standardized to ≥2 × 10¹⁰ CFU/g dried yeast. Unlike probiotics with plant origins, this strain is cultivated from yeast cultures specifically isolated for therapeutic use.

Historical & Cultural Context

No historical or traditional medicine use is documented for CBS 5926. It is a modern isolated strain developed specifically for clinical probiotic applications like Perenterol, without any referenced traditional context in Ayurveda, TCM, or other traditional medicine systems.

Health Benefits

• Reduces acne severity with 74.3% achieving good/very good outcomes vs 21.7% placebo in 5-month RCT (Strong evidence, PMID: 2530145)
• Effective for acute diarrhea, traveler's diarrhea, and tube-feeding diarrhea based on controlled studies (Moderate evidence)
• Safe in pediatric cystic fibrosis patients on antibiotics with no fungemia or adverse events (Moderate evidence, PMID: 7477086)
• Meta-analysis of 27 RCTs (5029 adults) showed 84% efficacy in placebo-controlled arms for various gastrointestinal conditions (Strong evidence)
• Protects against bacterial infections through immune modulation and pathogen antagonism in animal models (Preliminary evidence)

How It Works

Saccharomyces cerevisiae CBS 5926 produces bioactive compounds including B-vitamins, amino acids, and short-chain fatty acids that strengthen intestinal barrier integrity. The strain modulates the gut-skin axis by reducing inflammatory cytokines and enhancing beneficial microbiota populations. It also competitively excludes pathogenic bacteria and stimulates secretory IgA production for enhanced immune function.

Scientific Research

A randomized double-blind placebo-controlled trial in 139 acne patients demonstrated 74.3% achieving very good/good outcomes with CBS 5926 vs 21.7% placebo over 5 months (PMID: 2530145). In pediatric cystic fibrosis patients, 750 mg/day for 21 days proved safe without fungemia (PMID: 7477086). Broader meta-analyses of S. boulardii including CBS 5926 encompassing 27 RCTs with 5029 adults showed significant efficacy in 84% of placebo-controlled arms.

Clinical Summary

A 5-month randomized controlled trial demonstrated that 74.3% of participants achieved good to very good acne improvement versus 21.7% with placebo (PMID: 2530145). Multiple controlled studies show effectiveness for acute diarrhea, traveler's diarrhea, and tube-feeding-associated diarrhea, though specific effect sizes vary by condition. The strain has been safely tested in pediatric cystic fibrosis patients. Evidence quality ranges from moderate to strong depending on the specific indication studied.

Nutritional Profile

Saccharomyces cerevisiae CBS 5926 (the specific probiotic strain used in Perenterol/Hansen CBS 5926) is a non-pathogenic yeast delivered in lyophilized or dried form, typically in 250mg capsules/sachets. As a yeast-based organism, its compositional profile includes: Protein: ~40-50% dry weight, comprising all essential amino acids including lysine, threonine, and tryptophan. Carbohydrates: ~35-45% dry weight, predominantly as cell wall polysaccharides including beta-1,3/1,6-glucans (~30-35% of cell wall) and mannoproteins/mannans (~40-50% of cell wall), which are key bioactive structural components. Chitin contributes ~1-3% of cell wall. Lipids: ~4-7% dry weight, including phospholipids and ergosterol (provitamin D2 precursor). B-vitamins are naturally present: thiamine (B1) ~1-10 mcg/g, riboflavin (B2) ~4-8 mcg/g, niacin (B3) ~40-60 mcg/g, pantothenic acid (B5) ~10-20 mcg/g, pyridoxine (B6) ~2-5 mcg/g, folate ~1-3 mcg/g, and biotin ~0.1-0.5 mcg/g. Minerals include zinc (~50-100 mcg/g), selenium (variable, strain-dependent), chromium, iron, and potassium. Key bioactive compounds relevant to its probiotic activity include secretory IgA-stimulating mannoproteins, beta-glucans (immune-modulating), and caprylic acid. As a live probiotic yeast, bioavailability of its structural components is limited by resistance to digestion; the intact cells exert effects primarily through luminal and mucosal interactions rather than systemic nutrient absorption. Typical therapeutic dose is 250-500mg (approximately 1-5 billion CFU equivalent) per day; caloric contribution is negligible at therapeutic doses.

Preparation & Dosage

Clinically studied forms include lyophilized powder or capsules standardized to ≥2 × 10¹⁰ CFU/g. For diarrhea: 250 mg capsule or powder, typically 750 mg/day (250 mg three times daily). For acne: dosage aligned with 250 mg forms used in other studies. Duration ranges from 21 days to 5 months depending on indication. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lactobacillus rhamnosus GG, Zinc, Vitamin D3, Prebiotics (FOS/Inulin), Glutamine

Safety & Interactions

Saccharomyces cerevisiae CBS 5926 is generally well-tolerated with minimal reported adverse effects in clinical trials. Individuals with compromised immune systems or central venous catheters should avoid use due to rare risk of fungemia. No significant drug interactions have been reported, though antifungal medications may reduce probiotic viability. Safety during pregnancy and lactation has not been established through controlled studies.